Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Human embryonal stamcelle-afledt kardiomyocytterapi for kronisk iskæmisk venstre ventrikulær dysfunktion (HECTOR)

16. november 2026 opdateret af: Joseph C. Wu

Et fase I, randomiseret pilotstudie af humane embryonale stamcelle-afledte kardiomyocytter (hESC-CM'er) hos patienter med kronisk iskæmisk venstre ventrikulær dysfunktion sekundært til myokardieinfarkt (HECTOR)

This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).

Studieoversigt

Detaljeret beskrivelse

The phase I dose-escalation pilot study is intended as an initial safety assessment to establish the MTD prior to the phase II randomized, double-blinded, placebo-controlled study. An estimated eighteen (18) patients in phase I who are scheduled to undergo cardiac catheterization and have met all inclusion/exclusion criteria will be enrolled.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

18

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • California
      • Palo Alto, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford Hospital and Clinics

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Be ≥ 21 and < 80 years of age.
  • Provide written informed consent.
  • Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to MI as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.
  • Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.
  • Have been treated with appropriate maximal medical therapy for heart failure or postinfarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs) or have appropriate medical indication precluding use of one or both of these agents, the patient must have been on a stable dose of a clinically appropriate agent for 1 month or within no more than doubling the dose of any of ARB, ACE inhibitors, and ARNIs over the last 3 months.
  • Left ventricular ejection fraction below 40%.
  • Class II/III NYHA symptoms of heart failure within the 6 months prior to baseline testing.
  • Hospitalization in the past 6 months or NT pro-BNP > 1200 pg/mL, or >1600 pg/mL if atrial fibrillation was present.
  • Automated implantable cardioverter-defibrillator (AICD) in place.

Exclusion Criteria:

  • Have a baseline glomerular filtration rate < 35 ml/min/1.73 m2
  • Have a known, serious radiographic contrast allergy.
  • Have a prosthetic aortic valve or heart constrictive device.
  • Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5 cm2 or less).
  • Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
  • Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second- or third-degree heart block in the absence of a functioning pacemaker) or QTc interval > 550 ms on screening ECG.
  • AICD firing in the past 60 days prior to enrollment.
  • Be eligible for or require coronary artery revascularization.
  • Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/µl, or platelet values < 100,000/µl without another explanation.
  • Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN.
  • Have a coagulopathy (INR > 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR < 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment.
  • Have known allergies to penicillin or streptomycin.
  • Be an organ transplant recipient.
  • Have a history of organ or cell transplant rejection.
  • Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease-free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
  • Have a non-cardiac condition that limits lifespan to < 1 year.
  • Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.
  • Be serum-positive for HIV, hepatitis BsAg, or viremic hepatitis C.
  • Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
  • Be a female patient who is pregnant, nursing, or have child-bearing potential but is not using effective birth control.
  • Tested positive for SARS-CoV-2 within the last 30 days

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Cohort 1

Low dose (50M cells)

50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.

Andre navne:
  • Menneskelige ESC-CM'er
Aktiv komparator: Cohort 2

Medium dose (150M cells)

150M cells delivered in a dose of 15M cells per injection over 10 injections

Andre navne:
  • Menneskelige ESC-CM'er
Aktiv komparator: Cohort 3

High dose (300M cells)

300M cells delivered in a dose of 30M per injection over 10 injections

Andre navne:
  • Menneskelige ESC-CM'er

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The maximum tolerated dose (MTD) among 3 dose levels of allogeneic human embryonic stem cell-derived cardiomyocytes (hESC-CMs)
Tidsramme: 3 Years

The primary endpoints are safety and feasibility. The feasibility of preparing and delivering the study product, as well as collecting cardiac MRI variables in subjects will be assessed.

3 Years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. marts 2022

Primær færdiggørelse (Anslået)

1. oktober 2029

Studieafslutning (Anslået)

1. oktober 2029

Datoer for studieregistrering

Først indsendt

24. september 2021

Først indsendt, der opfyldte QC-kriterier

24. september 2021

Først opslået (Faktiske)

6. oktober 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner